Literature DB >> 19597972

Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice.

Xueming Wu1, Yi Feng, Eun-Kee Jeong, Lyska Emerson, Zheng-Rong Lu.   

Abstract

PURPOSE: To investigate the efficacy of polydisulfide-based biodegradable macromolecular contrast agents of different degradability and molecular weight for tumor characterization based on angiogenesis using dynamic contrast enhanced MRI (DCE-MRI).
METHODS: Biodegradable macromolecular MRI contrast agents, Gd-DTPA cystamine copolymers (GDCC) and Gd-DTPA cystine copolymers (GDCP), with molecular weight of 20 and 70 KDa were evaluated for tumor characterization. Gd(DTPA-BMA) and a prototype of macromolecular contrast agent, albumin-(Gd-DTPA), were used as controls. The DCE-MRI studies were performed in nude mice bearing MDA PCa 2b and PC-3 human prostate tumor xenografts. Tumor angiogenic kinetic parameters including endothelium transfer coefficient (K(trans)) and fractional tumor plasma volume (f(PV)) were calculated from the DCE-MRI data using a two-compartment model and compared between the two different tumor models for each contrast agent.
RESULTS: There was no significant difference in the f(PV) values between two tumor models estimated with the same agent except for GDCC-70. The K(trans) values in both tumor models decreased with the increase of molecular weight of contrast agents. With the same high molecular weight (70 KDa), GDCC-70 showed a higher K(trans) values than GDCP-70 due to high degradability of the former in both tumor models (p < 0.05). The K(trans) values of MDA PCa 2b tumors were significantly higher than those of PC-3 tumors estimated by Gd(DTPA-BMA), GDCC-20, GDCC-70, GDCP-70, and albumin-(Gd-DTPA) (p < 0.05).
CONCLUSIONS: The polydisulfide-based biodegradable macromolecular MRI contrast agents are promising in tumor characterization and differentiation with dynamic contrast enhanced MRI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597972      PMCID: PMC2805017          DOI: 10.1007/s11095-009-9935-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights.

Authors:  M Y Su; A Mühler; X Lao; O Nalcioglu
Journal:  Magn Reson Med       Date:  1998-02       Impact factor: 4.668

2.  Cancer statistics, 1988.

Authors:  E Silverberg; J A Lubera
Journal:  CA Cancer J Clin       Date:  1988 Jan-Feb       Impact factor: 508.702

3.  Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique.

Authors:  D M Shames; R Kuwatsuru; V Vexler; A Mühler; R C Brasch
Journal:  Magn Reson Med       Date:  1993-05       Impact factor: 4.668

4.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

5.  A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies.

Authors:  A A Bogdanov; R Weissleder; H W Frank; A V Bogdanova; N Nossif; B K Schaffer; E Tsai; M I Papisov; T J Brady
Journal:  Radiology       Date:  1993-06       Impact factor: 11.105

6.  Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density.

Authors:  C F van Dijke; R C Brasch; T P Roberts; N Weidner; A Mathur; D M Shames; J S Mann; F Demsar; P Lang; H C Schwickert
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

7.  Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.

Authors:  H Daldrup; D M Shames; M Wendland; Y Okuhata; T M Link; W Rosenau; Y Lu; R C Brasch
Journal:  AJR Am J Roentgenol       Date:  1998-10       Impact factor: 3.959

Review 8.  Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?

Authors:  D M Quinlan; A W Partin; P C Walsh
Journal:  Urology       Date:  1995-09       Impact factor: 2.649

9.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Authors:  N M Navone; M Olive; M Ozen; R Davis; P Troncoso; S M Tu; D Johnston; A Pollack; S Pathak; A C von Eschenbach; C J Logothetis
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

10.  Dynamics of tumor imaging with Gd-DTPA-polyethylene glycol polymers: dependence on molecular weight.

Authors:  T S Desser; D L Rubin; H H Muller; F Qing; S Khodor; G Zanazzi; S W Young; D L Ladd; J A Wellons; K E Kellar
Journal:  J Magn Reson Imaging       Date:  1994 May-Jun       Impact factor: 4.813

View more
  10 in total

1.  MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Authors:  Mingqian Tan; Susan M Burden-Gulley; Wen Li; Xueming Wu; Daniel Lindner; Susann M Brady-Kalnay; Vikas Gulani; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

2.  Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.

Authors:  Juan L Vivero-Escoto; Kathryn M L Taylor-Pashow; Rachel C Huxford; Joseph Della Rocca; Christie Okoruwa; Hongyu An; Weili Lin; Wenbin Lin
Journal:  Small       Date:  2011-11-09       Impact factor: 13.281

3.  Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.

Authors:  Anthony S Malamas; Erlei Jin; Qi Zhang; John Haaga; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2015-04-04       Impact factor: 4.200

4.  Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.

Authors:  Xueming Wu; Yuda Zong; Zhen Ye; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

5.  Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents.

Authors:  Zheng-Rong Lu; Xueming Wu
Journal:  Isr J Chem       Date:  2010-08       Impact factor: 3.333

6.  Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents.

Authors:  Mingqian Tan; Zhen Ye; Eun-Kee Jeong; Xueming Wu; Dennis L Parker; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2011-04-19       Impact factor: 4.774

7.  Characterization of tumor vascular permeability using natural dextrans and CEST MRI.

Authors:  Yuguo Li; Yuan Qiao; Hanwei Chen; Renyuan Bai; Verena Staedtke; Zheng Han; Jiadi Xu; Kannie W Y Chan; Nirbhay Yadav; Jeff W M Bulte; Shibin Zhou; Peter C M van Zijl; Guanshu Liu
Journal:  Magn Reson Med       Date:  2017-11-28       Impact factor: 4.668

Review 8.  Sugar-based biopolymers as novel imaging agents for molecular magnetic resonance imaging.

Authors:  Zheng Han; Guanshu Liu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-01-22

9.  CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans.

Authors:  Hanwei Chen; Dexiang Liu; Yuguo Li; Xiang Xu; Jiadi Xu; Nirbhay N Yadav; Shibin Zhou; Peter C M van Zijl; Guanshu Liu
Journal:  Magn Reson Med       Date:  2019-05-20       Impact factor: 3.737

Review 10.  Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Yuling Yan; Xilin Sun; Baozhong Shen
Journal:  Oncotarget       Date:  2017-06-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.